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INTRODUCTION
Visceral leishmaniasis (VL) is a severe disease caused by protozoa
of the genus Leishmania that usually affects immunocompetent
hosts in endemic areas [1,2]. Since the mid-1980s, VL has been
recognized as an opportunistic infection associated with some
immunodeﬁciency states, such as neoplasms, organ transplanta-
tion, or treatment with immunosuppressive agents [3,4]. VL
has also been recognized as a common complication of patients
infected with the human immunodeﬁciency virus (HIV) [5–15].
There have been numerous reports on HIV-related VL [16–27],
but some aspects of its epidemiology, clinical features, diagnosis
and therapeutic management have not been completely clari-
ﬁed. In this paper, we review the main topics concern-
ing the epidemiology, clinical presentation and therapy of
AIDS-related VL.
EP IDEMIOLOGY AND DEMOGRAPHIC FEATURES
Leishmaniasis is an endemic disease in the Mediterranean basin,
where it usually affects immunocompetent individuals, fre-
quently children [28]. A slight increase in the incidence of
VL and in the proportion of cases among the adult population
has been recently detected in southern Europe [5,28].
Since the mid-1980s, VL has been increasingly reported as a
complication of AIDS. As of 1999, more than 1400 cases of
HIV–leishmania co-infection had been reported, over 90% of
the published cases reported worldwide being observed in
Spain, Italy and France [5–7]. This has been interpreted as a
result of the high degree of overlap between the two infections
in this area. Epidemiologic changes, such as the increased
population density in suburban areas, where the vector is
widespread and dogs are abundant, have facilitated a growing
overlap of VL and AIDS [5,27]. Cases of co-infection have also
been reported from other areas of the world, such as India,
Brazil, East Africa and South America, as well as in HIV-
infected patients traveling to these endemic areas [13,27].
The increase in the incidence of co-infection in these areas,
due to the expansion of the AIDS epidemic in VL endemic
regions, is a matter of concern. The main epidemiologic and
demographic data of the main published series are summarized
in Table 1.
Since leishmaniasis is not included among the AIDS-deﬁning
diseases, little information on its actual prevalence is available
through AIDS case notiﬁcation systems. Since 1998, the World
Health Organization has established an active surveillance
program to assess the global impact of HIV–leishmania co-
infection [5]. Epidemiologic data have revealed that the inci-
dence of VL has progressively increased in southern Europe, and
this ﬁnding seems to be related to cases associated with HIV
infection, which has become the main risk factor for VL in this
area [17]. This increase parallels the trend of the AIDS epidemic
observed in Spain and other countries of southern Europe. A
recent study has demonstrated that, in endemic areas such as
France, around 10% of HIV-infected individuals have asympto-
matic leishmania infection [29], and it has been estimated that
between 2% and 9% of all AIDS patients in southern Europe
will develop VL [6]. Recent reports have revealed that in the
Madrid area about two-thirds of VL cases reported in the last
10 years have been associated with HIV infection [17].
HIV-related VL usually appears in patients with advanced
immunosuppression, supporting the opportunistic role of leish-
maniasis in HIV-infected individuals. About half of the patients
(between 33% and 78%) have AIDS-deﬁning criteria before the
diagnosis of VL [18,19,21,23,30]. The mean CD4þ lympho-
cyte count is 25–204/mL, and is less than 200/mL in 62–100% of
the patients (Table 1). However, VL may appear in HIV-
infected patients with different degrees of immunodeﬁciency,
both in asymptomatic HIV carriers and in patients with deﬁ-
nitive AIDS [9,19,21,27].
Almost all cases of co-infection have been described in adult
patients with HIV-1, but some cases have also been diagnosed in
patients with HIV-2 and in children [27]. Leishmania infantum is
the species most frequently isolated in co-infected patients in
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Table1 Epidemiologic and demographic features of HIV-associated visceral leishmaniasis
CD4 lymphocytesc
Author (year) Reference
Number of
patients
Geographic
area
Prevalencea
(%)
Male sex
(%)
Mean age
(years)
IVDA
(%)
AIDSb
(%) Mean <200 (%)
WHO (1999) 5 818 World ND 83 ND 71 ND ND 91
Pasquau et al. (2000) 16 160 Spain 3.4 82 34 73 61 ND 88
Gradoni et al. (1996) 10 115 Italy 1.6 85 32 84 67 ND 93
Rosenthal et al. (2000) 8 91 France ND 86 38 43 64 56 ND
Pintado et al. (2001) 17 80 Spain 2.3 80 33 79 54 90 89
Lo¤ pez-Ve¤ lez et al. (1998) 18 54 Spain 2.7 85 31 78 46 96 89
Peters et al. (1990) 12 47 Europe ND 77 30 82 34 ND ND
Medrano et al. (1992) 19 47 Spain 8.5 81 33 66 66 ND 87
Laguna et al. (1997) 20 43 Spain 2.1 98 ND 81 67 ND 79
Montalba¤ n et al. (1990) 21 40 Spain ND 90 29 92 47 204 ND
Delgado et al. (1997) 50 31 Spain 4.2 97 34 68 58 38 100
Jover et al. (2000) 22 22 Spain ND 89 31 100 86 68 ND
Agostoni et al. (1998) 11 20 Italy ND 95 33 75 70 41 95
Ribera et al. (1995) 23 20 Spain ND 75 28 50 60 69 90
Reus et al. (1999) 24 19 Spain 4.3 72 32 58 58 50 95
Albrecht et al. (1996) 13 14 Germany ND 93 38 36 ND 37 100
Sanz et al. (1991) 25 12 Spain ND 92 27 100 33 152 66
Dereure et al. (1995) 14 10 France ND 70 36 ND 78 66 100
IVDA, intravenous drug abuser; ND, no data.
aPercentage of patients with leishmaniasis among AIDS cases. bPrevious or simultaneous AIDS at the moment of diagnosis of visceral leishmaniasis. cCells/mL.
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southern Europe, but cases of infection with L. donovani, L.
braziliensis, L. aethiopica, L. tropica or L. major have also been
reported in other areas of the world [7,27].
Demographic data of co-infected patients reﬂect the epide-
miologic features of HIV infection in the Mediterranean
countries (Table 1). The mean age of co-infected patients ranges
from 27 to 38 years, and 70–100% are male. The most common
risk factor for HIV infection is intravenous drug addiction (50–
100%), but VL has been also described in other risk groups, such
as homosexuals, heterosexuals with unsafe sexual practices, and
recipients of blood products [5,7,27]. The greater frequency of
co-infection among intravenous drug users [26,30] has given
rise to hypotheses that the drug addiction habit may play a
speciﬁc role in leishmania transmission [27]. Whereas this result
may simply reﬂect the higher proportion of HIV-infected drug
addicts in this area, there is mounting evidence for the possi-
bility of this form of transmission.
PATHOGENESIS OF CO- INFECTION
It is well known that the cell-mediated immune response largely
determines the outcome of Leishmania infection, and therefore
only a minority of infected individuals develop clinically
apparent visceral disease. The prevalence of VL among AIDS
patients is, however, signiﬁcantly higher than that in immuno-
competent individuals (100–2320 times higher) and other groups
of immunosuppressed patients [5,9,10,17,18]. HIV-related VL
usually appears in patients with advanced immunosuppression,
and two mechanisms have been proposed to explain the asso-
ciation between leishmaniasis and HIV-related immuno-
deﬁciency [13,27].
Immunosuppression can lead to clinical leishmaniasis by two
mechanisms: (1) allowing the reactivation of a latent infection,
in a similar manner to most AIDS-associated opportunistic
infections; or (2) facilitating the development of the active
disease after the primary infection [21,27].
The ﬁrst hypothesis is supported by the frequent antecedent
of a remote episode of leishmaniasis, reported in 4–33% of co-
infected patients [21,26,31], and the appearance of VL in other
immunosuppressed patients living in non-endemic areas,
several years after traveling to endemic areas [13]. The second
hypothesis is based on the higher frequency of VL among HIV-
infected intravenous drug abusers documented in some Spanish
reports [30], which supports the possibility of parenteral
human-to-human transmission via contact with needles con-
taminated by blood infected with Leishmania. The hypothesis of
an increased risk of disease after primary infection might also
explain the cases of VL produced by dermotropic strains of L.
infantum [9], the high variability of Leishmania isolates and the
appearance of new zymodemes of the parasite [27,32], and the
infections produced by apparently non-pathogenic ﬂagellates
[27] described in HIV-infected patients. Concerning the
sequence of acquisition, previous reports have documented
that HIV-related VL may occur either after primary leishmania
infection [31] or as a result of the reactivation of a latent
infection [29], and prospective studies are necessary to clarify
this point.
CLINICAL AND ANALY TIC FEATURES
Although it has been proposed that VL in immunocompro-
mised hosts shows different clinical manifestations lacking
visceromegalies or fever [3], most HIV-infected patients have
the clinical features of classic disease. Table 2 summarizes the
main clinical and analytic features of HIV-associated VL. Two
recent comparative studies have shown that the clinical features
of VL in HIV-infected individuals closely resemble those in
immunocompetent hosts, and that most HIV–leishmania co-
infected patients had fever, hepatosplenomegaly and/or pancy-
topenia [17,24]. It is noteworthy that leishmaniasis may present
as fever of unknown origin; VL has been reported as a cause of
this syndrome in 7–23% of HIV-infected individuals [33].
Some authors have reported the unusual or atypical clinical
manifestations of VL in HIV-infected patients as compared to
those observed in immunocompetent subjects [6,8,9]. Because
of the severely immunocompromised condition of these
patients, the parasite can spread to tissues that it usually does
not inhabit, due to the absence of an efﬁcient immune response
system, and colonize atypical locations. A broad spectrum of
atypical sites of infection has been reported in this population,
including widely disseminated mucocutaneous, gastrointestinal,
pulmonary, laryngeal, renal, peritoneal, synovial and cerebral
involvement [8,27,34]. The most common reported site has
Table2 Clinical and analytic features of visceral leishmaniasis associated
with HIV infection
Clinical features Frequency (%)
Fever 67^100
Constitutional symptoms 31^90
Hepatomegaly 49^100
Splenomegaly 65^100
Adenopathy 12^57
Atypical features 10^34
Skin involvement 8^18
Lung involvement 6^25
Digestive tract involvement 7^18
Analytic features
Anemia 77^100
Leukopenia 75^95
Thrombocytopenia 70^92
Lymphocytopenia 78^81
Pancytopenia 35^82
Hypergammaglobulinemia 40^88
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been the skin, with the appearance of cutaneous leishmaniasis
concomitant with VL in 8–18% of HIV-associated VL cases
[9,21]. In contrast, exclusive cutaneous or mucocutaneous
leishmaniasis is uncommon in AIDS patients, occurring in less
than 3% of all cases of co-infection [7]. In addition, some
authors have reported that VL may be diagnosed fortuitously in
19–27% of HIV-infected patients while examining concurrent
HIV-related diseases [8,20].We believe that sites of involvement
of HIV-related VL are similar to those observed in immuno-
competent patients. Most of the ‘atypical’ forms of leishmaniasis
described in HIV-infected patients should not be classiﬁed in
this way, because although now rarely observed, the majority
have previously been described with variable frequency in
immunocompetent subjects [2]. Larger comparative studies are
needed to establish whether these manifestations of VL aremore
frequent in AIDS patients that in the general population.
It is noteworthy that other concomitant opportunistic infec-
tions are diagnosed in 42–68% of HIV-infected patients with VL
[9,15,19,23]. This ﬁnding is not unexpected, since most cases of
VL appear when the patient is seriously immunodepressed. The
clinical symptoms of VL can therefore be masked by conco-
mitant opportunistic infections in HIV-infected individuals,
making the diagnosis of leishmaniasis even more difﬁcult.
Pancytopenia is a characteristic feature of VL, and most co-
infected patients have some type of hematologic cytopenia
(Table 2). Some reports have shown that the frequency and
degree of anemia, leukopenia, lymphopenia and thrombocy-
topenia are greater in HIV-infected patients that in immuno-
competent individuals [17,24]. HIV infection is associated with
a wide spectrum of hematologic abnormalities, and hemato-
logic cytopenia is a frequent ﬁnding in advanced AIDS. The
cause of these abnormalities is multifactorial, and factors such as
direct effect of the virus, ineffective hematopoiesis, inﬁltrative
disease of the bone marrow, nutritional deﬁciencies, peripheral
consumption and drug effects may explain the more frequent
and pronounced hematologic cytopenia found in HIV-related
VL. Hypergammaglobulinemia secondary to B-cell polyclonal
activation is a frequent ﬁnding in both VL and HIV infection
[1,2], and thus the presence of a high gammaglobulin level has a
limited diagnostic value in HIV-infected patients with suspected
VL. As described above, most HIV-infected patients had
advanced immunosuppression at the moment of diagnosis of
VL, and, therefore, lymphopenia, a low CD4þ lymphocyte
count, and a decreased CD4þ to CD8þ ratio is observed in
most patients.
DIAGNOSTIC PROCEDURES
The diagnostic yields of the different diagnostic procedures in
HIV-related VL are summarized in Table 3. Splenic aspiration is
considered the most sensitive method for the diagnosis of VL,
and some reports have shown good results with this procedure
in HIV-infected patients [6,18]. However, although complica-
tions occur in fewer than 1% of the cases, the risk associated
with this procedure is a matter of concern, and thus the
experience with this procedure is sparse in European countries.
Bone marrow aspirate has been the most frequently employed
diagnostic technique in co-infected patients. The reported
sensitivities for bone marrow aspirate, biopsy and bone marrow
culture have been 62–93%, 38–80%, and 50–100%, respectively
(Table 3).
The diagnostic yield of these techniques in co-infected
patients is similar to that reported in the general population
[17,24]. The slightly lower yield of the bone marrow aspirate in
HIV-infected patients reported in some series [17,18] could be
explained by the hypoplasic bone marrow frequently present in
advanced AIDS. The high sensitivity of bone marrow culture,
which may be the only positive technique in up to 15% of
patients, has led some authorities to recommend its routine use
in HIV-infected patients, especially when relapse is suspected.
In agreement with previous reports [5,7,9,12], we consider that
the elective diagnostic technique for HIV-related VL is bone
marrow aspirate with parasitic culture, since not only VL but
other causes of fever of unknown origin can be diagnosed.
Some reports have shown the high diagnostic yield of splenic
aspiration samples [6,18], the direct examination of peripheral
blood smears [20], and buffy-coat parasitic culture [18,35]
(Table 3), but other studies have not conﬁrmed these promising
results. In addition, the sensitivity of these techniques seems to
be lower in relapsing cases [7,20]. The slightly lower sensitivity
Table3 Diagnostic yield of the different diagnostic procedures for visceral
leishmaniasis associated with HIV infection
Diagnostic procedure Sensitivity (%)
Bonemarrow
Aspirate 62^93
Biopsy 38^80
Culture 50-100
PCR 82^100
Splenic aspirate 85^100
Liver biopsy 68^87
Lymph node biopsy 38^50
Skin biopsy 75^89
Peripheral blood smear 50^53
Peripheral blood PCR 97^100
Blood culture 25^89
Serology
Indirect immunofluorescence 22^68
Direct hemagglutination 16^68
ELISA 22^58
Dot-ELISA 72^78
Western blot 80^100
ELISA, enzyme-linked immunosorbent assay; PCR, polymerase chain
reaction.
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of liver, lymph node and skin biopsies in HIV-related VL has
been established in previous studies [5,18,19,21].
Finally, indirect xenodiagnosis[36], leukocytoconcentration
of peripheral blood [37], and polymerase chain reaction [38,39]
have been applied to the diagnosis of VL in HIV-infected and
non-HIV-infected patients, with promising results. However,
because these techniques are not feasible for most clinicians,
bone marrow aspiration or biopsy is therefore considered the
procedure of ﬁrst choice for the diagnosis of VL in our setting.
The low yield of serologic studies is one of the most chara-
cteristic ﬁndings of HIV-related VL; between 43% and 78%
of these patients show no detectable levels of anti-Leishmania
antibodies [9,18,19,21]. This surprising result is in great con-
trast with the ﬁndings in immunocompetent or other groups
of immunodeﬁcient individuals, where signiﬁcantly positive
titers are found in 87–95% of cases [1–4]. These data suggest
that the value of serology as a method for detecting Leishmania
is limited in HIV-infected individuals. Better results have
been reported in recent studies with the use of highly sensitive
techniques, such as enzyme-linked immunosorbent assay [6,9],
Western blotting [40], and experimental immunoﬂuorescence
tests [31] (Table 3). The combination of two or more serologic
techniques may signiﬁcantly increase the sensitivity of antibody
detection, and some authorities have recommended this prac-
tice in HIV-infected patients with suspected VL. However, in a
study in which several diagnostic methods were compared, 20%
of co-infected patients gave negative results with all serologic
techniques [39]. The functional impairment of cell-mediated
immunity due to HIV infection could result in an absent
antibody response to Leishmania, as for other infections. How-
ever, the humoral immune response of co-infected patients is
extremely variable and apparently independent of the degree of
immunosuppression, the clinical stage of AIDS, or the outcome
of infection. Gradoni et al suggested that the serologic response
could be related to the sequence of temporal acquisition of
the infectious agents [31]. Seropositivity would represent a
reactivation of latent infection, acquired before the immune
depression caused by the HIV, while seronegativity would
result from primary leishmania infection acquired after HIV
infection.
TREATMENT AND RESPONSE
Despite the high number of reported cases of HIV-related VL,
the treatment of choice, the best dosage and the duration of
therapy have been not established [6]. Most published reports
have been retrospective studies, and it is difﬁcult to reach
reliable conclusions about the efﬁcacy and toxicity of the
different therapeutic regimens. Although the criteria used to
evaluate the response have been variable in previous reports,
one of the most relevant ﬁndings of HIV-associated VL was the
lower response rate to therapy. Previous studies have reported
that only 38–87% of co-infected patients achieve a clinical
response [9,15,18,23,41] and that a parasitologic response is
observed in 38–81% of cases [18,19,41]. In addition, some
authors have encountered many difﬁculties in evaluating the
clinical response to treatment of VL in HIV-infected indivi-
duals, due to the simultaneous occurrence of multiple oppor-
tunistic infections and treatments, early death, toxicity, or being
lost to follow-up. The results of therapy of the main published
series are listed in Table 4.
Pentavalent antimonial agents (PAs) are the ﬁrst-choice
therapy for VL in the Mediterranean area [28], and therefore
they have been frequently used in co-infected patients. The
World Health Organization’s recommended treatment with
antimonial compounds (20mg of SbV/kg per day, with a maxi-
mum daily dose of 850mg in adults) seemed to be ineffective for
most HIV-infected patients. Higher antimonial doses (20mg of
SbV/kg per day, with no upper-limit daily dose) have been
recommended for immunocompetent patients [28,42], and
some reports have shown that this treatment could be most
effective in HIV-related VL [12,20,43]. Amphotericin B has
been used as a second-line treatment for only a limited number
of HIV-infected patients, and some studies have reported good
results [9,18,20].
A recent randomized trial comparing PA (20mg SbV/kg per
day) with amphotericin B (0.7mg/kg per day), both for
4weeks, showed that the efﬁcacy of both regimens was similar
in HIV-related VL [44]. An initial cure rate was attained in 66%
and 62% of the patients treated with PA and amphotericin B,
respectively. A similar response rate (58% for PA and 61% for
amphotericin B) has been reported in a recent retrospective
study [17].
The frequent treatment failures among HIV-infected patients
demonstrate the need for alternative therapies. A broad spec-
trum of drugs has been used in HIV-related VL, such as
liposomal amphotericin B [45,46], pentamidine [13,15], PA
in combination with allopurinol [43], aminosidine [12], inter-
feron-g [47], ketoconazole, allopurinol alone or in combination
with azole compounds [17,24], and many others, with variable
results. Liposomal amphotericin B has been used in HIV-
infected patients, with promising results. However, after the
excellent results initially obtained, with a response rate higher
than 80%, later studies showed that most patients relapsed in the
long term [46,48]. In the future, liposomal amphotericin B
could become a ﬁrst-line drug for VL, although at present its
high cost limits its use. Moreover, no comparative studies on the
efﬁcacy and toxicity have been reported to recommend the use
of alternative therapies.
There are few reports that analyze the toxicity of therapy of
HIV-related VL [17,18]. Occasional cases of serious adverse
events have been reported, but it is unknown whether HIV-
infected patients present adverse events more frequently and/or
with greater severity than immunocompetent patients. In a
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recent prospective study [44], the frequencies of serious toxicity
of PA and amphotericin B were similar (55% and 60%, respec-
tively). The patients treated with PA had a higher incidence of
cardiotoxicity and hyperamylasemia, while nephrotoxicity and
anemia were more frequent in patients receiving amphotericin
B. Antimonial-induced pancreatic toxicity has been recently
described in immunocompetent and AIDS patients, and there
have been some cases of fatal acute pancreatitis. It is remarkable
that a high proportion of patients receiving therapy for VL
develop an adverse event that precludes the continuation of
treatment [17,20,44].
REL APSES
One of the most outstanding features of HIV-associated VL is its
tendency to relapse, observed in 25–61% of patients; some
patients followed a chronic course with multiple relapses despite
treatment with multiple drugs and regimens of secondary
prophylaxis. VL relapse is a early event, and occurs in the ﬁrst
year after the diagnosis in most patients [12,13,16,21,23–25]. A
similar high relapse rate has been observed in other immuno-
suppressed patients, such as transplant recipients [4]. This
relapsing course is probably due to the reactivation of the
process caused by the inability of the immune system to
eradicate the infection, with persistence of latent infection after
an apparent cure [21]. In some instances, the development of
drug resistance could contribute to the therapeutic failure and
relapsing course observed in HIV-infected patients. The char-
acterization of sequential isolates of Leishmania from HIV-
infected patients has shown that they belong to the same
zymodeme, indicating that infections are due to relapses and
not to reinfections [32].
A relapsing course does not seem to depend on the clinical
features of the infection, the degree of immunosuppression, or
the presence of AIDS [19,21,23]. Previous studies have found
that this protracted course of HIV-related VL may be associated
with some risk factors, such as the presence of anti-Leishmania
antibodies [21], the occurrence of a ﬁrst VL relapse [49], female
gender [16], non-completed therapy for a VL episode [16], and
the absence of secondary prophylaxis for VL [16,17,49].
The clinical presentation and the sensitivity of the diagnostic
procedures in VL relapses seem to be comparable to those of
initial episodes [7,17,18,50]. However, the higher index of
clinical suspicion concerning the diagnosis may explain the
shorter duration of the symptoms before diagnosis in relapses
[17,50]. A broad spectrum of drugs has been used for the
therapy of relapses in HIV-infected patients (high-dose PA,
alone or in combination with allopurinol or interferon-g,
amphotericin B, liposomal amphotericin B, etc.) [12,13,15,
24,43,47]. Although the efﬁciency of second-line treatments
under these circumstances has not been adequately explored,
the response rate to the therapy with either PA or amphoteri-
cin B is comparable to that observed in the initial episodes
[17,18].
Table4 Treatment and response of visceral leishmaniasis in HIV-infected patients
Author (year) Reference
Number of
patients
Therapy
(dose and duration) Response (%)a
Pentavalent antimonialsb
Lo¤ pez-Ve¤ lez et al. (1998)c 18 51 20mg/kg/day (4 weeks) 82
Laguna et al. (1999) 44 44 20mg/kg/day (4 weeks) 66
Montalba¤ n et al. (1990) 21 40 20mg/kg/day (3 weeks)d 75
Pintado et al. (2001)e 17 35 20mg/kg/day (3^4 weeks)d 58
Rosenthal et al. (1995) 9 24 20mg/kg/day (3 weeks) 50
Berhe et al. (1999) 54 23 20mg/kg/day (4 weeks) 74
Ribera et al. (1995)f 23 20 20mg/kg/day (3 weeks)d 100
Laguna et al. (1997) 20 20 20mg/kg/day (4 weeks) 80
Reus et al. (1999)g 24 21 20mg/kg/day (3 weeks)d 52
Amphotericin B deoxycholate
Laguna et al. (1999) 44 45 0.7mg/kg/day (4 weeks) 62
Reus et al. (1999) 24 20 15^25mg/kg (total dose) 85
Lo¤ pez-Ve¤ lez et al. (1998)h 18 17 15mg/kg (total dose) 82
Pintado et al. (2001) 17 16 0.5^1mg/kg/day (3^4 weeks) 61
Rosenthal et al. (1995) 9 12 20mg/kg (total dose) 100
Liposomal amphotericin B
Russo et al. (1996) 46 9 4mg/kg/day (10 days) 89
Laguna et al. (1995) 48 5 4mg/kg/day (10 days) 80
aThe criteria used to assess the responsewere different in some reports. bPentavalent antimony dose. c Three patients received allopurinol and two interferon-
g. dMaximum daily dose of 850mg/day in most patients. eSix patients received interferon-g and four allopurinol. fFive patients received allopurinol. gNine
patients received allopurinol. hFour patients were treated with liposomal amphotericin B.
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SECONDARY PROPHYL AXIS
The high relapse rate of AIDS-related VL has led to the
empirical use of different maintenance regimens, but the
optimal regimen for secondary prophylaxis has not yet been
established. Allopurinol [23], liposomal amphotericin B [51],
antimonials [49], pentamidine [18] and azole compounds
[13,24] have been used as prophylactic drugs in HIV-infected
individuals, with variable results. Unfortunately, all reported
studies have been retrospective, with an open design, and have
included few patients, making it difﬁcult to reach reliable
conclusions. In a recent non-randomized, retrospective study
[49], the probability of remaining relapse-free at 12months was
9% without prophylaxis, 21% with daily allopurinol, and 93%
with monthly pentavalent antimony. Another retrospective
study has shown that patients receiving either monthly PA
or liposomal amphotericin B have a signiﬁcantly lower relapse
rate than patients receiving no prophylaxis [17]. Although
prospective randomized trials are necessary to determine the
best regimen for secondary prophylaxis in HIV-related VL, the
routine use of secondary prophylaxis seems to be advisable in
these patients, PA and amphotericin B being the drugs that
could be most effective in this situation.
OUTCOME AND PROGNOSTIC FACTORS
The different clinical course, mostly related to the higher relapse
and mortality rates, and the shortened survival are the most
noteworthy characteristics of HIV-associated VL. Before the
introduction of the new antiretroviral therapies, the mortality in
co-infected patients was very high. Overall mortality has varied
between 24% and 60% [12,16,18,20,21,26], and it is note-
worthy that between 10% and 27% of patients died during the
ﬁrst month after the diagnosis of VL [18,20]. Although most
patients died from other AIDS-related diseases such as con-
comitant opportunistic infections or complications of therapy, it
is conceivable that leishmaniasis contributed to the poor out-
come, either by causing immunosuppression independent of
HIV or by stimulating HIV replication.
The outcome of VL depends on the development of speciﬁc
cellular immunity by T-lymphocytes, which secrete different
cytokines in response to antigenic stimulation. The Th1-type
response, mediated by interleukin-2, interleukin-12, and inter-
feron-g, leads to the activation of macrophages and enhanced
intracellular killing of parasites, whereas the predominance of
Th2-type cytokines, such as interleukin-4 and interleukin-10, is
associated with progressive disease [52]. The association
between leishmaniasis and HIV infection is a logical conse-
quence of cellular immunodeﬁciency. The Th1-type response
is severely impaired in patients with advanced HIV infection. In
addition, active Leishmania infection induces a prolonged Th2-
type cell activation in HIV-infected patients which determines
an increase in viral replication and a progressive decrease in
CD4þ lymphocytes [53,54], supporting the notion that co-
infection plays an important role in the pathogenesis and disease
progression of both infections.
Although antiparasitic treatment seems to restore cytokine
production in immunocompetent hosts, this may not be the
case if T-helper lymphocytes are primarily affected, as happens
in HIV infection [27]. In such cases, the treatment may not be
effective in killing intracellular parasites, thus explaining the
unsuccessful response and the chronic-relapsing course of VL in
HIV-infected patients. The progressive immunodeﬁciency
associated with co-infection may modify the natural history
of HIV infection, as demonstrated by the fact that between 44%
and 75% of patients with relapsing leishmaniasis will develop
AIDS in the months following the diagnosis of VL [21,23,53].
The mean survival time in co-infected patients varies from 3
to 25months [6,7,13,15,21,25], and the probability of being
alive 12months after the ﬁrst episode is approximately 60%.
Previous studies have found some factors that may inﬂuence the
mortality, such as the diagnosis of AIDS [18,21,23], the presence
of severe AIDS-related diseases [20], the CD4þ lymphocyte
count [16,17,20], the degree of thrombocytopenia at the
moment of diagnosis of VL [18], the use of secondary pro-
phylaxis for VL [16,17], antiretroviral therapy [17], and the
chronic-relapsing course [21]. In two recent studies, the survival
of HIV-infected patients with VL but without AIDS was similar
to that of patients with other AIDS-deﬁning illness but without
VL [16,18], a ﬁnding that emphasizes the prognostic signiﬁcance
and opportunistic nature of VL in this population.
HAART AND HIV-REL ATED VISCERAL
LEISHMANIASIS
Highly active antiretroviral therapy (HAART) has been widely
used in HIV-infected patients since 1996, and this treatment has
led to a striking reduction in morbidity and mortality among
AIDS patients. There has been an overall reduction of the
incidence of major opportunistic infections, changes in man-
ifestations of some infections, and improvement in clinical
outcomes. The beneﬁcial effect of HAART has also been
demonstrated in other parasitic infections such as cryptospor-
idiosis and toxoplasmosis, and some recent reports have began
to show the beneﬁcial impact of HAARTon the epidemiology
and outcome of AIDS-related VL.
Two recent reports from Spain and Italy have demonstrated a
decreasing incidence of VL among HIV-infected patients after
the widespread use of this therapy [55,56]. Another recent study
has demonstrated a signiﬁcant improvement in the survival of
HIV–leishmania co-infected patients receiving HAART [57].
In addition, immune reconstitution after HAART may allow
the withdrawal of secondary prophylaxis for VL in patients with
a CD4 lymphocyte count higher than 200/mL [58]. Unfortu-
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nately, a high relapse rate of VL (26–70%) has been observed in
co-infected patients, despite the use of HAART [17,59,60]. In
the near future, the widespread use of HAART and the
implementation of secondary prophylaxis for VL can contribute
to a progressive decrease in the morbidity and mortality of
HIV-associated VL.
VISCERAL LEISHMANIASIS AS AN
AIDS-DEFINING DISEASE
The increased incidence and the different clinical course of VL
among HIV-infected individuals have led some authorities and
the European Committee of the World Health Organization to
propose the inclusion of VL among the AIDS diagnostic criteria
[6,7,18,23,41]. Most studies have demonstrated that VL behaves
as an opportunistic infection in HIV-infected patients, and that
its epidemiologic and clinical features closely resemble those of
other AIDS-related infections. HIV-related VL has a clear
epidemiologic relation with HIV infection, it usually appears
in the presence of profound immunodeﬁciency, and it has a
different clinical outcome in HIV-infected individuals, char-
acterized by high relapse and mortality rates, and shortened
survival. The possible inclusion of VL as a diagnosis criterion for
AIDS in HIV-infected patients should therefore be considered
an open question.
CONCLUSIONS AND FUTURE DIRECTIONS
Visceral leishmaniasis has become a common complication
among AIDS patients living in endemic areas, where it behaves
as an opportunistic infection in this population. The immu-
nologic and virologic aspects of co-infection with HIV–Leish-
mania comprise one of the most important areas of research that
should be explored in the near future. Although new antire-
troviral therapy has begun to change the epidemiology and the
prognosis of AIDS-related leishmaniasis, we need improved
diagnostic tests to detect the disease, as well as new drugs, more
effective and less toxic, for the treatment and prophylaxis of this
infection.
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